vs
Absci Corp（ABSI）与bioAffinity Technologies, Inc.（BIAF）财务数据对比。点击上方公司名可切换其他公司
bioAffinity Technologies, Inc.的季度营收约是Absci Corp的2.5倍（$1.6M vs $650.0K）。bioAffinity Technologies, Inc.净利率更高（-197.0% vs -4548.0%，领先4351.0%）。Absci Corp同比增速更快（-2.3% vs -27.8%）。bioAffinity Technologies, Inc.自由现金流更多（$-2.6M vs $-29.3M）。过去两年Absci Corp的营收复合增速更高（-14.9% vs -18.6%）
Absci Corp是一家结合合成生物学与人工智能技术的生物技术企业，为全球制药及生物制药合作伙伴提供集成式蛋白质工程解决方案，加速抗体、治疗性蛋白等新型生物候选药物的研发，助力满足未被覆盖的临床医疗需求。
bioAffinity Technologies是一家处于临床阶段的生物技术企业，专注于研发可用于癌症、呼吸系统疾病早期检测的非侵入性体外诊断产品，面向全球医疗市场，致力于提供高准确率的便捷诊断方案，改善患者诊疗体验与预后效果。
ABSI vs BIAF — 直观对比
营收规模更大
BIAF
是对方的2.5倍
$650.0K
营收增速更快
ABSI
高出25.6%
-27.8%
净利率更高
BIAF
高出4351.0%
-4548.0%
自由现金流更多
BIAF
多$26.7M
$-29.3M
两年增速更快
ABSI
近两年复合增速
-18.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $650.0K | $1.6M |
| 净利润 | $-29.6M | $-3.1M |
| 毛利率 | — | — |
| 营业利润率 | -4775.5% | -196.9% |
| 净利率 | -4548.0% | -197.0% |
| 营收同比 | -2.3% | -27.8% |
| 净利润同比 | -2.0% | -5.7% |
| 每股收益（稀释后） | $-0.19 | $-3.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABSIBIAF
| Q4 25 | $650.0K | $1.6M | ||
| Q3 25 | $378.0K | $1.4M | ||
| Q2 25 | $593.0K | $1.3M | ||
| Q1 25 | $1.2M | $1.9M | ||
| Q4 24 | $665.0K | $2.2M | ||
| Q3 24 | $1.7M | $2.4M | ||
| Q2 24 | $1.3M | $2.4M | ||
| Q1 24 | $898.0K | $2.4M |
净利润ABSIBIAF
| Q4 25 | $-29.6M | $-3.1M | ||
| Q3 25 | $-28.7M | $-5.1M | ||
| Q2 25 | $-30.6M | $-4.1M | ||
| Q1 25 | $-26.3M | $-2.7M | ||
| Q4 24 | $-29.0M | $-3.0M | ||
| Q3 24 | $-27.4M | $-2.0M | ||
| Q2 24 | $-24.8M | $-2.1M | ||
| Q1 24 | $-22.0M | $-2.0M |
营业利润率ABSIBIAF
| Q4 25 | -4775.5% | -196.9% | ||
| Q3 25 | -7977.2% | -158.6% | ||
| Q2 25 | -5293.9% | -198.2% | ||
| Q1 25 | -2351.9% | -141.7% | ||
| Q4 24 | -4477.3% | -133.5% | ||
| Q3 24 | -1698.7% | -84.0% | ||
| Q2 24 | -2104.0% | -87.1% | ||
| Q1 24 | -2616.7% | -80.8% |
净利率ABSIBIAF
| Q4 25 | -4548.0% | -197.0% | ||
| Q3 25 | -7594.2% | -349.3% | ||
| Q2 25 | -5155.0% | -319.9% | ||
| Q1 25 | -2234.6% | -143.5% | ||
| Q4 24 | -4358.3% | -134.4% | ||
| Q3 24 | -1610.7% | -85.1% | ||
| Q2 24 | -1948.8% | -88.0% | ||
| Q1 24 | -2447.1% | -81.5% |
每股收益（稀释后）ABSIBIAF
| Q4 25 | $-0.19 | $-3.59 | ||
| Q3 25 | $-0.20 | $-4.74 | ||
| Q2 25 | $-0.24 | $-0.17 | ||
| Q1 25 | $-0.21 | $-0.16 | ||
| Q4 24 | $-0.26 | $-17.27 | ||
| Q3 24 | $-0.24 | $-4.84 | ||
| Q2 24 | $-0.22 | $-0.19 | ||
| Q1 24 | $-0.22 | $-0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $6.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $189.4M | $7.3M |
| 总资产 | $216.3M | $11.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABSIBIAF
| Q4 25 | $144.3M | $6.4M | ||
| Q3 25 | $152.5M | $7.7M | ||
| Q2 25 | $38.0M | $802.8K | ||
| Q1 25 | $47.0M | $444.7K | ||
| Q4 24 | $112.4M | $1.1M | ||
| Q3 24 | $38.2M | $756.6K | ||
| Q2 24 | $42.9M | $801.3K | ||
| Q1 24 | $58.8M | $2.5M |
总债务ABSIBIAF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $4.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ABSIBIAF
| Q4 25 | $189.4M | $7.3M | ||
| Q3 25 | $210.3M | $8.9M | ||
| Q2 25 | $173.4M | $-2.1M | ||
| Q1 25 | $198.8M | $1.4M | ||
| Q4 24 | $179.1M | $2.6M | ||
| Q3 24 | $201.3M | $3.1M | ||
| Q2 24 | $221.5M | $3.4M | ||
| Q1 24 | $240.1M | $5.3M |
总资产ABSIBIAF
| Q4 25 | $216.3M | $11.0M | ||
| Q3 25 | $245.0M | $11.5M | ||
| Q2 25 | $209.9M | $4.8M | ||
| Q1 25 | $232.4M | $5.5M | ||
| Q4 24 | $213.6M | $6.5M | ||
| Q3 24 | $235.2M | $6.6M | ||
| Q2 24 | $255.5M | $6.7M | ||
| Q1 24 | $274.9M | $8.0M |
负债/权益比ABSIBIAF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-29.2M | $-2.6M |
| 自由现金流经营现金流 - 资本支出 | $-29.3M | $-2.6M |
| 自由现金流率自由现金流/营收 | -4505.4% | -160.7% |
| 资本支出强度资本支出/营收 | 15.8% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-94.2M | $-9.4M |
8季度趋势，按日历期对齐
经营现金流ABSIBIAF
| Q4 25 | $-29.2M | $-2.6M | ||
| Q3 25 | $-25.0M | $-2.5M | ||
| Q2 25 | $-16.9M | $-2.6M | ||
| Q1 25 | $-21.8M | $-1.6M | ||
| Q4 24 | $-17.0M | $-1.7M | ||
| Q3 24 | $-20.7M | $-1.7M | ||
| Q2 24 | $-16.8M | $-1.5M | ||
| Q1 24 | $-17.9M | $-2.3M |
自由现金流ABSIBIAF
| Q4 25 | $-29.3M | $-2.6M | ||
| Q3 25 | $-26.0M | $-2.5M | ||
| Q2 25 | $-17.1M | $-2.7M | ||
| Q1 25 | $-21.9M | $-1.7M | ||
| Q4 24 | $-17.0M | $-1.7M | ||
| Q3 24 | $-20.8M | $-1.7M | ||
| Q2 24 | $-17.2M | $-1.6M | ||
| Q1 24 | — | $-2.4M |
自由现金流率ABSIBIAF
| Q4 25 | -4505.4% | -160.7% | ||
| Q3 25 | -6876.5% | -171.8% | ||
| Q2 25 | -2883.0% | -209.6% | ||
| Q1 25 | -1854.5% | -91.3% | ||
| Q4 24 | -2554.4% | -76.0% | ||
| Q3 24 | -1221.6% | -73.1% | ||
| Q2 24 | -1352.4% | -65.1% | ||
| Q1 24 | — | -99.2% |
资本支出强度ABSIBIAF
| Q4 25 | 15.8% | 0.0% | ||
| Q3 25 | 254.5% | 0.3% | ||
| Q2 25 | 37.6% | 1.1% | ||
| Q1 25 | 2.1% | 2.7% | ||
| Q4 24 | 3.5% | 0.0% | ||
| Q3 24 | 2.8% | 0.4% | ||
| Q2 24 | 26.2% | 1.2% | ||
| Q1 24 | 0.0% | 1.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
